EMA committee recommends orphan drug status for Erytech product
The drug, which is used to treat sickle cell disease, increases the oxygenation properties of red blood cells by reducing their oxygen-hemoglobin affinity and allowing them to release
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).
As part of the agreement, Full Spectrum Genetics protein analysis and engineering platform, MapEng, and BioBlocks’ fragment based drug discovery platform technology,Fragment-to-Lead, will be combined. The technologies will